SK Bioscience wins patent lawsuit against Pfizer (PFE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Pfizer (PFE) PT Raised to $33 at Jefferies
May 21, 2025 8:19 AM EDTJefferies analyst Akash Tewari raised the price target on Pfizer (NYSE: PFE) to $33.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "PFE announced an exclusive global licensing agreement w/ 3SBio for SSGJ-707 (PD-1/VEGF). We like the deal for PFE:... More



